A serious complication of bisphosphonate (BP) therapy is BP-related osteonecrosis of the jaw (BRONJ). Currently, no biomarkers exist to identify patients at risk. We evaluated whether interleukin-17 and C-telopeptide correlate with BRONJ development. We conducted a case-control study using patients with a history of BP therapy. Quantitative enzyme-linked immunosorbent assay and Student's t-test were done. Both markers were significantly higher in BRONJ, suggesting altered immune responses and bone remodeling may play roles in BRONJ development.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
case-control study
8
bronj development
8
bronj
5
evaluation serum
4
serum biomarkers
4
biomarkers il-17
4
il-17 ctx
4
ctx bronj
4
bronj pilot
4
pilot clinical
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!